Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Thomas E Ichim
AddedMar 31, 2024
UpdatedMay 1, 2026
Thomas E Ichim

Thomas E Ichim

Board Member, Creative Medical Technology Holdings

Thomas E Ichim's Career

Creative Medical Technology Holdings
Creative Medical Technology Holdings

Phoenix, AZ, US

Board Member· Board
Therapeutic Solutions International
Therapeutic Solutions International

Oceanside, CA, US

Board Member· Board
Batu Biologics
Batu Biologics

San Diego, CA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Thomas E Ichim's Career

Creative Medical Technology Holdings
Creative Medical Technology Holdings
Public41998Phoenix, AZ, US
Board Member· Board

Leadership at Creative Medical Technology Holdings

Donald DickersonDonald DickersonBoard Member
Timothy WarbingtonTimothy WarbingtonFounder & CEO
Dr Amit N PatelDr Amit N PatelBoard Member

Similar to Creative Medical Technology Holdings

Stemedica Cell TechnologiesStemedica Cell TechnologiesSan Diego, CA, USCell Therapy, Therapeuticsest. 2005Stemedica Cell TechnologiesSan Diego, CA, US · est. 2005

Stemedica Cell Technologies: Developing and commercializing cell and protein therapies for medical needs.

Series B · $67M175
StemcyteStemcyteBaldwin Park, CA, USStem Cell Productsest. 1997StemcyteBaldwin Park, CA, US · est. 1997

US-based StemCyte Inc. provides umbilical cord blood stem cell products for life-threatening disease treatments.

Public · $2.5M750
CelviveCelvivePrinceton, NJ, USStem Cell Therapyest. 2011CelvivePrinceton, NJ, US · est. 2011

Celvive, Inc.: Pioneering regenerative medicine with a focus on neural regeneration since 2011.

Angel · $225k5
Cellebration Life SciencesCellebration Life SciencesSan Diego, CA, USStem Cell Therapiesest. 2020Cellebration Life SciencesSan Diego, CA, US · est. 2020

Celebration: A pre-clinical R&D firm specializing in targeted stem-cell therapies for degenerative conditions.

Seed · $2.8M5
Therapeutic Solutions International
Therapeutic Solutions International
Public$10.1M52007Oceanside, CA, US
Board Member· Board

Leadership at Therapeutic Solutions International

Tim G DixonTim G DixonBoard Member

Similar to Therapeutic Solutions International

Total Nutraceutical SolutionsTotal Nutraceutical SolutionsSherwood, OR, USCosmetics, Nutraceuticalsest. 2007Total Nutraceutical SolutionsSherwood, OR, US · est. 2007

TNS: Innovating organic nutraceutical and cosmetic products for enhanced health and beauty.

Public · $2.3M6
PanTheryxPanTheryxBoulder, CO, USMedical Products, Nutritional Supplementsest. 2007PanTheryxBoulder, CO, US · est. 2007

US-based PanTheryx, Inc. manufactures medical products for diverse health conditions, serving global healthcare professionals.

Public · $190.3M75
NutranomicsNutranomicsDraper, UT, USNutritional Productsest. 2007NutranomicsDraper, UT, US · est. 2007

Nutranomics Inc.: A leading nutraceutical manufacturer specializing in nutritional food R&D.

Public32
Platinum BiosciencesPlatinum BiosciencesPlano, TX, USCBD Products, Nutraceuticalsest. 2019Platinum BiosciencesPlano, TX, US · est. 2019

Platinum BioSciences crafts top-quality, pharmacist-compounded, hemp-infused nutraceuticals for optimal health results.

Angel · $250k30
Batu Biologics
Batu Biologics
Pre-Seed$2.8M62013San Diego, CA, US
CEO· C-Suite · Management

Leadership at Batu Biologics

Alan LewisAlan LewisBoard Member
Nimesh GoelNimesh GoelBoard Member
Vladimir BoginVladimir BoginBoard Member
Dr John ChiplinDr John ChiplinBoard Member

Similar to Batu Biologics

Cell BioEnginesCell BioEnginesNew York City, NY, USCell Therapiesest. 2022Cell BioEnginesNew York City, NY, US · est. 2022

Cell BioEngines, Inc.: A clinical-stage biotech firm innovating cancer cures with scalable cell therapies.

Pre-Seed · $625k6
ImmuneBridgeImmuneBridgeSan Francisco, CA, USCancer Therapiesest. 2018ImmuneBridgeSan Francisco, CA, US · est. 2018

ImmuneBridge pioneers in developing allogeneic immunotherapies for cancer using cord blood-derived stem cells.

Seed · $12M16
Immpact BioImmpact BioCamarillo, CA, USCAR T-Cell Therapyest. 2017Immpact BioCamarillo, CA, US · est. 2017

ImmPACT Bio: Innovating transformative CAR-T cell therapies for advanced cancer patients.

Series B · $129M105
Platelet BioGenesisPlatelet BioGenesisWatertown, MA, USCell Therapyest. 2014Platelet BioGenesisWatertown, MA, US · est. 2014

US-based PlateletBio pioneers in allogeneic cell therapy, innovating superior solutions for unmet medical challenges.

Series B · $132.1M39

Thomas E Ichim's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Thomas E Ichim

Mike TomasMike TomasBoard Member · U.S. Stem CellJeff ConroyJeff ConroyCEO · Innovative BiologicsThomas von KochThomas von KochBoard Member · EQTTim MullaneTim MullaneCEO · BiologJunichi SugiharaJunichi SugiharaCEO · BioimpactJosep Bassaganya-RieraJosep Bassaganya-RieraBoard Member · Landos Biopharma